Literature DB >> 17823658

Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.

Guey-Shin Wang1, Debra L Kearney, Mariella De Biasi, George Taffet, Thomas A Cooper.   

Abstract

Myotonic dystrophy type 1 (DM1) is caused by a CTG trinucleotide expansion in the 3' untranslated region (3' UTR) of DM protein kinase (DMPK). The key feature of DM1 pathogenesis is nuclear accumulation of RNA, which causes aberrant alternative splicing of specific pre-mRNAs by altering the functions of CUG-binding proteins (CUGBPs). Cardiac involvement occurs in more than 80% of individuals with DM1 and is responsible for up to 30% of disease-related deaths. We have generated an inducible and heart-specific DM1 mouse model expressing expanded CUG RNA in the context of DMPK 3' UTR that recapitulated pathological and molecular features of DM1 including dilated cardiomyopathy, arrhythmias, systolic and diastolic dysfunction, and mis-regulated alternative splicing. Combined in situ hybridization and immunofluorescent staining for CUGBP1 and CUGBP2, the 2 CUGBP1 and ETR-3 like factor (CELF) proteins expressed in heart, demonstrated elevated protein levels specifically in nuclei containing foci of CUG repeat RNA. A time-course study demonstrated that colocalization of MBNL1 with RNA foci and increased CUGBP1 occurred within hours of induced expression of CUG repeat RNA and coincided with reversion to embryonic splicing patterns. These results indicate that CUGBP1 upregulation is an early and primary response to expression of CUG repeat RNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823658      PMCID: PMC1964514          DOI: 10.1172/JCI32308

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

Review 1.  Structure and function of cardiac potassium channels.

Authors:  D J Snyders
Journal:  Cardiovasc Res       Date:  1999-05       Impact factor: 10.787

2.  Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein.

Authors:  D S Sohal; M Nghiem; M A Crackower; S A Witt; T R Kimball; K M Tymitz; J M Penninger; J D Molkentin
Journal:  Circ Res       Date:  2001-07-06       Impact factor: 17.367

3.  In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.

Authors:  M Fardaei; K Larkin; J D Brook; M G Hamshere
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

4.  The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient to disrupt C2C12 myoblast differentiation.

Authors:  J D Amack; M S Mahadevan
Journal:  Hum Mol Genet       Date:  2001-09-01       Impact factor: 6.150

5.  Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.

Authors:  A Mankodi; C R Urbinati; Q P Yuan; R T Moxley; V Sansone; M Krym; D Henderson; M Schalling; M S Swanson; C A Thornton
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

6.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

7.  Molecular basis for impaired muscle differentiation in myotonic dystrophy.

Authors:  N A Timchenko; P Iakova; Z J Cai; J R Smith; L T Timchenko
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

8.  RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1.

Authors:  N A Timchenko; Z J Cai; A L Welm; S Reddy; T Ashizawa; L T Timchenko
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

9.  Dynamic antagonism between ETR-3 and PTB regulates cell type-specific alternative splicing.

Authors:  Nicolas Charlet-B; Penny Logan; Gopal Singh; Thomas A Cooper
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

10.  Muscleblind proteins regulate alternative splicing.

Authors:  Thai H Ho; Nicolas Charlet-B; Michael G Poulos; Gopal Singh; Maurice S Swanson; Thomas A Cooper
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

View more
  105 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity.

Authors:  Gloria V Echeverria; Thomas A Cooper
Journal:  Brain Res       Date:  2012-02-22       Impact factor: 3.252

Review 3.  RNA-mediated neurodegeneration in repeat expansion disorders.

Authors:  Peter K Todd; Henry L Paulson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

Review 4.  Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders.

Authors:  Huiping Tan; Zihui Xu; Peng Jin
Journal:  Exp Neurol       Date:  2012-01-27       Impact factor: 5.330

Review 5.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

Review 6.  CELFish ways to modulate mRNA decay.

Authors:  Irina Vlasova-St Louis; Alexa M Dickson; Paul R Bohjanen; Carol J Wilusz
Journal:  Biochim Biophys Acta       Date:  2013-01-15

7.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

Review 8.  Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

Review 9.  Pathogenic mechanisms of myotonic dystrophy.

Authors:  Johanna E Lee; Thomas A Cooper
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

10.  PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.

Authors:  Guey-Shin Wang; Muge N Kuyumcu-Martinez; Satyam Sarma; Nitin Mathur; Xander H T Wehrens; Thomas A Cooper
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.